Fulcrum Therapeutics (FULC) Accumulated Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accumulated Expenses data on file, last reported at $5.0 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 210.34% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 210.34% increase from a year earlier, with the FY2025 full-year figure at $4.3 million, up 44.31% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.0 million, up from $4.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for FULC reached as high as $12.5 million in Q2 2022 and fell as low as $1.6 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $4.9 million in 2025.
• Across the five-year window, Accumulated Expenses jumped 261.45% in 2023 and sank 77.66% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $9.6 million in 2022, then slipped by 8.64% to $8.7 million in 2023, then sank by 65.76% to $3.0 million in 2024, then jumped by 44.31% to $4.3 million in 2025, then gained by 14.87% to $5.0 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $5.0 million in Q1 2026, $4.3 million in Q4 2025, and $6.4 million in Q3 2025.